{"ticker": {"uuid": "f531bb70-c519-4499-b8a6-e31121bbe5d8", "symbol": "GDTC", "name": "CytoMed Therapeutics Limited Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)", "summary": "This article is a 6-K report from CytoMed Therapeutics, submitted by a foreign private issuer. These reports are related to financial reporting obligations. The content of this particular filing is a document.", "url": "https://www.moomoo.com/news/notice/306927683/cytomed-therapeutics-6-k-report-of-foreign-private-issuer-related", "source_name": "Moomoo", "published_at": "2026-07-13T10:10:38", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Climbs 5.1% as Shares Approach Resistance at $1.08 - Max Pain Level", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdmo4OFlrR2xiLWNTLVlZSUUtZ2hEQ19zeWgtMUd3dnEwTVR2ZFJfQlhNTzlBTUxmOFJ3MXd2Z3BtSTlTZDlJLWxQcjB6SDBYZXoyN2JvUUl0OUhNSzVBTmdpMko4cFNFMXVEbTA1QkE3N3JzanhHUm9Rby1aMGJ6b1J4YmxRZjNDRnA3cnN6U2NKSlVTSVlWNUtZWWxjS1hVWFd2WlI5YV9kT2l1cDNIX2c2WUZZUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T18:46:27+00:00", "published_display": "12 Jul 2026 18:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxNSTFCMlJGcEpUcEdfSWNlSHZIVjM5X1lKLXFtM1VreHktdko2cEZDcV9ramhXa0ZsYnRpUVdXQkp3S3F4dk9adERIcno5eWtkZ3RuUVZaZzVtSTdmTzdpNjhjUFE4ckI2Zm5UVDhnLU84ckFRTkVnTW40UEFUZVZfczMxUmltZE1xdjk4Y3dDeEd2RTNmaEhoMDhNSlhLTy1tMXJ4UXFWQjUtc1VacGdJM2twU2pnMFVWVm5MVHdZd0NnTFJ2T2s5cTZlOFhhWndMa05qcmRLQkdVZ3Fmd1loS0NxUkctMkF1ekI5Y1BrTVRManVKbnVWSkNfWXJKc3JSbWdQdDhZVC14Q3BmSncza1BOWkdldVptUkhoelE5Zkw1TUp4dkxuY2xR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T16:15:00+00:00", "published_display": "10 Jul 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Stock Forecast & Analyst Ratings", "summary": "This article provides a stock forecast and analyst ratings for CytoMed Therapeutics (GDTC). It includes key metrics such as the stock price, market cap, 52-week range, volume, and average volume. The article also touches upon the company's financial performance, analyst price tar", "url": "https://www.moomoo.com/stock/GDTC-US/forecast?chain_id=Name1K9-3FXPhg.1l0a440&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A59,%22f%22%3A%22www.moomoo.com%2Foptions%2FCOHR260501C330000-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-10T16:41:18", "published_display": "10 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of CytoMed Therapeutics Limited \u2013 NASDAQ:GDTC", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOM3dOWXJwWjF3QkIwdFBYaGhHQWxhNk9UT1R2OS0wZjY2QzlJVUlHMEJvVm1FeUF0QjVaQUh6MDlya2FUVXVUZFNxejNpQUszTmRJTV8waFlfNzBRMTJnUDNfYW5FSjVfd0dyQS1iVktFdEJVMmwxeVhHcDl5UDFBOFhDY0lpWkJzc3VTbWI1S2JLWlFYTEhyZDV0ekl1c19FVkl0UkN3c2ZaNC1MZFE?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T04:10:56+00:00", "published_display": "10 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (NASDAQ: GDTC) \u2013 A Rising Star in Singapore\u2019s Cancer Biotechnology Sector", "summary": "CytoMed Therapeutics Ltd (NASDAQ: GDTC), a clinical-stage biotech company, is making strides in developing affordable cancer therapies using patented allogeneic Gamma Delta T Cells. The company is currently conducting clinical trials in Singapore and plans to expand to Malaysia, ", "url": "https://www.financialcontent.com/article/getnews-2026-7-9-cytomed-therapeutics-ltd-nasdaq-gdtc-a-rising-star-in-singapores-cancer-biotechnology-sector", "source_name": "FinancialContent", "published_at": "2026-07-09T18:39:57", "published_display": "09 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC - CytoMed Therapeutics Ltd Options", "summary": "This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its last close price, market capitalization, income, sales, key financial ratios, and stock performance metrics. It lists various operational and financial indicators, such as ROA, R", "url": "https://finviz.com/stock?t=GDTC&p=d&b=2&ty=oc", "source_name": "Finviz", "published_at": "2026-07-06T16:09:27", "published_display": "06 Jul 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC - CytoMed Therapeutics Ltd Volatility & Greeks", "summary": "This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's volatility and various financial ratios, offering a snapsho", "url": "https://finviz.com/stock?t=GDTC&b=2&p=d&r=m1&ty=ocv&e=2026-03-02", "source_name": "Finviz", "published_at": "2026-07-03T18:40:32", "published_display": "03 Jul 2026 18:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank", "summary": "CytoMed Therapeutics chairman, Choo Chee Kong, is increasing his personal stake in the company by acquiring up to 200,000 shares and also invested S$300,000 in CytoMed\u2019s subsidiary, LongevityBank Pte Ltd, through his wholly owned EP Capital Inc. This investment will double EP Cap", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GDTC-Q/pressreleases/2631074/cytomed-chairman-boosts-personal-stake-and-funds-rd-expansion-at-longevitybank/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T16:09:27", "published_display": "27 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Limited Actuals & Estimates (NASDAQ:GDTC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOaW5keFV3amwtM01uQ0JXNF85NHlDb0NFM3VmdDVqS3dKUVRjNFB2YjNjS3VvV3lHWHZ1VUkwWGRHSVFpVVZiTmh2VnUxSzRhMy1iNlhhSkFuU2pYbmRwMFJFcFBCOUFDdXdFYWNtLWVMMUtRNnc0OE9uQ3JxbDlkWVZtQ1dJUQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T05:09:55+00:00", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K CytoMed Therapeutics Ltd For: 23 June", "summary": "This article announces the filing of Form 6K by CytoMed Therapeutics Ltd for June 23. It includes disclaimers about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate and that investors should be f", "url": "https://m.uk.investing.com/news/stock-market-news/form-6k-cytomed-therapeutics-ltd-for-23-june-93CH-4740808?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T22:10:44", "published_display": "23 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com", "summary": "This article provides details of a Form 6K filing by CytoMed Therapeutics Ltd for June 23. The content is brief, primarily serving as a notification of the filing, and includes general financial market data such as indices, commodities, bonds, and shares, which are not directly r", "url": "https://ng.investing.com/news/stock-market-news/form-6k-cytomed-therapeutics-ltd-for-23-june-93CH-2570533", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T17:24:00", "published_display": "23 Jun 2026 17:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D", "summary": "CytoMed Therapeutics' Chairman and Director, Choo Chee Kong, plans to acquire up to 200,000 company shares through private cash transactions, demonstrating increased personal exposure to the stock. Separately, his entity, EP Capital Inc., invested S$300,000 (approximately US$250,", "url": "https://www.stocktitan.net/sec-filings/GDTC/6-k-cyto-med-therapeutics-ltd-current-report-foreign-issuer-1ca287e3e827.html", "source_name": "Stock Titan", "published_at": "2026-06-23T16:10:16", "published_display": "23 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Holds Flat at $1.09 as Trading Range Narrows - Synthetic Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNM2NaQ3Ixb2N5ZUJIN2trSDg4ZGQxNEFDb0lrR1RWN2RzV3FZbnpSUXROd1R6LXU2aGxlOVBNcG9KVkNpcndMcnlBcFlEblZPcU1UNU9oYjF3SW1PY0RodU85QUdua2ppMHlTZ2RGZWQ0UnhsckNNQWJOdEFSbzN1QVZtV0tEQmZ3N0txbzI3UU5PbmhMOGRzcS1QVTlrZEVrYnZqQVFRdDlCdVZiLURwV0Vn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), focusing on support, resistance, indicators, and moving averages. It synthesizes various technical indicators like MACD, RSI, and MA to offer a comprehensive outlook. The analysis indicates a \"Sell\" si", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T08:11:11", "published_display": "18 Jun 2026 08:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides an analysis of CytoMed Therapeutics Ltd (GDTC) valuation metrics, specifically Price-to-Earnings (P/E), Price-to-Book (P/B), and Fair Value. It explicitly states that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. The p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:48", "published_display": "18 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for CytoMed Therapeutics Ltd (GDTC), focusing on future EPS and revenue growth estimates. It notes that relevant data has not yet been disclosed by the company, thus no forecast figures are available. However, analysts forecast a price t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:08:47", "published_display": "18 Jun 2026 06:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Institutional Confidence", "summary": "This article provides details on the institutional confidence in CytoMed Therapeutics Ltd (GDTC), including its stock performance, market capitalization, and key institutional shareholders. It lists several institutional investors and individual shareholders, along with their sha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:08:47", "published_display": "18 Jun 2026 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for CytoMed Therapeutics Ltd (GDTC), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Sharpe Ratio, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:21", "published_display": "18 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of CytoMed Therapeutics Ltd's (GDTC) shareholder structure, detailing major shareholders and institutional holdings. It lists the proportion held by key entities like Glorious Finance Limited and mDR Limited, alongside a breakdown by shareholder ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:32", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for CytoMed Therapeutics Ltd (GDTC), focusing on its business segments, regional revenue, and profit contribution. It states that relevant data for these categories have not yet been disclosed by the company. The page also includes current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:32", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market", "summary": "CytoMed Therapeutics director and ten percent owner Choo Chee Kong purchased 112,000 Ordinary Shares in an open-market transaction at $1.1498 per share, totaling $128,778. Following this acquisition, Choo Chee Kong directly owns 430,324 Ordinary Shares. The filing indicates a pos", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-4-cyto-med-therapeutics-ltd-insider-trading-activity-3910678c3d24.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:40:18", "published_display": "15 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: Director at $GDTC Buys 112,000 Shares | GDTC Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPeVpXWDBDb3hBaHdUbl85dnFSaHZPNnFqazh5NmN0TjgxRVg2a2lEcW51MlV6cDYxMndpTkFjYlJtb0tXZFV6dnA5cGNFR19za2FEcFA2amVrSkJIQ1ByMHAwWGZiU0tfZmVRLUZoUnU4eGVOYXB0b2diajRLbVpfSmVRMFpHLUdoRVE2cElKWERVVWpSX2ozZHZB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: Director at $GDTC Buys 112,000 Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxObUxZQmY0Rk5WUlNldURwTnlJakJwcWtRTEJkc0VjWXdBMGIwTUVQUmRHZjR0MTAyZmVVdXZaZHNUUTBnTnZSTDhLV1F1YWJ2OC1Eb29RRG9zeE5PRlFmWkt2TnY1Q0NHVVBIc0Zpb0JrcUI5VzlSZXhBVGFITzQxVkRPVU9JLTYwckJpeGNZSllDd3p1OXdnWEJ3?oc=5", "source_name": "Moomoo", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (Nasdaq:GDTC) - Stock Analysis", "summary": "This article provides a stock analysis of CytoMed Therapeutics (Nasdaq:GDTC), highlighting its status as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies. It details the company's financial performance, including declining earnings and an undervalu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gdtc/cytomed-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-05T02:09:12", "published_display": "05 Jun 2026 02:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals", "summary": "CytoMed Therapeutics (NASDAQ: GDTC) shareholders approved all ten proposals at its Annual General Meeting (AGM) held on May 22, 2026, in Singapore. These approvals included adopting financial statements, re-electing directors Dr. Yew Chak Hua and Dr. Toh Keng Kiat, waiving the Si", "url": "https://www.stocktitan.net/sec-filings/GDTC/6-k-cyto-med-therapeutics-ltd-current-report-foreign-issuer-56e566ca6d2b.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:40:30", "published_display": "03 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into Focus - Volume Dry Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNYnRHUTMxaGpYM1FfeGtlOG1TM0szWlFxUEk0LU1ZNDRlWTZzYkJHLXJlUm1PWnlJcGF2MGx0MTF1bkFKMVBYVGU3MHFkbUsxR3hPd01WSlBNc1BTenQ0S0RkbHBYVnAzRlA0MHJxc215eXd5NEF1SEZBSE5mcUw5c3poRnBZTjFJbTIyMTRTamYxUkcya3J3ME9Dc1lHckRYYkhwSFMtZ0JBM3AyMUMtVFpBMVUxWHJC?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC - CytoMed Therapeutics Ltd Stock Price and Quote", "summary": "This article provides a detailed stock price and quote for CytoMed Therapeutics Ltd (GDTC), including its last closing price, financial metrics, and recent news. It highlights various financial data points like market cap, income, sales, and insider ownership, alongside a chronol", "url": "https://finviz.com/stock?t=GDTC", "source_name": "Finviz", "published_at": "2026-06-01T00:14:03", "published_display": "01 Jun 2026 00:14", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares", "summary": "CytoMed Therapeutics director Toh Keng Kiat has reported an initial beneficial ownership of 4,000 Ordinary Shares in the company. This disclosure is a routine Form 3 filing with the SEC and signifies an existing holding rather than a new transaction. The shares are directly owned", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-2a9b9fb9de28.html", "source_name": "Stock Titan", "published_at": "2026-05-26T12:40:22", "published_display": "26 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd - A Rising Star in Singapore's Cancer Biotechnology Sector", "summary": "CytoMed Therapeutics Ltd, a clinical-stage biotech company based in Singapore, is making significant strides in developing affordable cancer therapies using allogeneic Gamma Delta T Cells. Through strategic acquisitions and a focus on global expansion, particularly in China and I", "url": "https://www.openpr.com/news/4521685/cytomed-therapeutics-ltd-a-rising-star-in-singapore-s-cancer", "source_name": "openPR.com", "published_at": "2026-05-21T10:40:13", "published_display": "21 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Limited is accelerating its international expansion", "summary": "CytoMed Therapeutics Limited is expanding its international presence, starting with a name change for its subsidiary to CytoMed International Pte. Ltd. The company aims to explore global opportunities, particularly in Asia and China, through potential joint ventures and medical t", "url": "https://www.openpr.com/news/4516247/cytomed-therapeutics-limited-is-accelerating-its", "source_name": "openPR.com", "published_at": "2026-05-18T05:39:09", "published_display": "18 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 3] CytoMed Therapeutics Ltd Initial Statement of Beneficial Ownership", "summary": "CytoMed Therapeutics Ltd's Chief Corporate Officer, Tan Yoong Ying, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 25,781 Ordinary Shares with no par value. This SEC filing indicates his existing stake without any recent purchase or ", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-547b5d7a2b42.html", "source_name": "Stock Titan", "published_at": "2026-05-15T22:09:18", "published_display": "15 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership", "summary": "CytoMed Therapeutics director Choo Chee Kong filed an initial Form 3 detailing his beneficial ownership in the company. The filing reports direct ownership of 318,324 Ordinary Shares and indirect ownership through Glorious Finance Limited (2,075,310 shares) and EP Capital Inc. (1", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-afcc166940b2.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:10:35", "published_display": "15 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares", "summary": "CytoMed Therapeutics' CFO, Yvonne Goh, has filed an initial insider ownership report (Form 3) showing she directly holds 25,781 Ordinary Shares in the company. This filing simply reports her existing stake and does not indicate any recent purchases, sales, or option exercises. Th", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-74ea2aa207c6.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:10:35", "published_display": "15 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3", "summary": "CytoMed Therapeutics director Yew Chak Hua has reported an initial ownership of 2,469 ordinary shares on Form 3, establishing his status as a director with a direct stake. This filing indicates current holdings upon becoming a director and does not reflect any recent buying or se", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-2287f13bdf01.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:10:34", "published_display": "15 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[144] CytoMed Therapeutics Ltd SEC Filing", "summary": "This article reports on a Form 144 SEC filing by CytoMed Therapeutics Ltd (GDTC). The filing indicates a proposed sale of 117,337 ordinary shares with an aggregate market value of $98,093.73, acquired on April 22, 2021, via a share subscription from the issuer. The sale is schedu", "url": "https://www.stocktitan.net/sec-filings/GDTC/144-cyto-med-therapeutics-ltd-sec-filing-704d6fc27a25.html", "source_name": "Stock Titan", "published_at": "2026-05-13T14:39:01", "published_display": "13 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "The page displays real-time and delayed quotes for CytoMed Therapeutics Ltd (GDTC) on Nasdaq, showing a current price of 0.809 USD with a 3.72% increase. It presents an overview of the company, financial data, and discussion sections, along with a market cap and P/E TTM informati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/comments", "source_name": "TradingKey", "published_at": "2026-05-11T19:40:32", "published_display": "11 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CytoMed Therapeutics Strengthens Future with Advanced Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOeE1RMy1ya3k5WFNwX05WcjB6NXhsbnpucmhhc21vRWIwTC14d2VRcDV5WVNlNFV2ckRmZHZ3aWxjc2xCWkZ2Y21rblg2NEJkeEdEX1B2WWZPOVJLUFNLNGVrZ0drNl9qUUFvVFoyUkVodXBXdUEybUoxMDFHenBzVk82TmpqYVZ6dER5RQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxOEp3YktYbS1xUlBQVUNTQWwya2FqcHNEOXBqVTRWSjBQT3Y5NmdvbVFMVjVyNWdGNm8ybkNXb1RFamRFb1hFZTlLdXZIQVMyOC1j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:24:35+00:00", "published_display": "25 Apr 2025 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC Stock Price and Chart \u2014 NASDAQ:GDTC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9iSmFjbDI4VjQzaVc5UTBpS3JoZUQzUlQ4OHRvemZaNXBGQ3cxdVZmd1JaeW1FRzZ6c1VoZC10eUtvRGZxR01zMmtad19WMDhQNHc5aGtDLWl6QzdS?oc=5", "source_name": "TradingView", "published_at": "2024-01-23T08:00:00+00:00", "published_display": "23 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Better Therapeutics (BTTX) Stock Up 39% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPbDhRalpFYmJqdzFxRVktanhUVHEzbFVLMEFvTXVmbHdlY0h3OWs2cXRRVEx4MkhCY2NpZkVkbmgyRlhYS1BCTFhGR2M5eWQ0NHRsS0hISWxGNGpTRnpMMjR1bHVtSUliZVJBc1dveWJvQVBHLU56bkxRRk9jWkE5a3B6WWF6UnBXREZ6ZQ?oc=5", "source_name": "InvestorPlace", "published_at": "2023-07-11T07:00:00+00:00", "published_display": "11 Jul 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9CNjZVTVVtR0JLQW9pcGdmYjdYNWhXT1JvWlRnOG9sMkRRcEZhSm11TXFkTWVlTHV0eTB6MVF6NENFQUFrc1FVLWhRT0c0UQ?oc=5", "source_name": "Stock Titan", "published_at": "2023-04-14T00:23:14+00:00", "published_display": "14 Apr 2023 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)", "summary": "This article is a 6-K report from CytoMed Therapeutics, submitted by a foreign private issuer. These reports are related to financial reporting obligations. The content of this particular filing is a document.", "url": "https://www.moomoo.com/news/notice/306927683/cytomed-therapeutics-6-k-report-of-foreign-private-issuer-related", "source_name": "Moomoo", "published_at": "2026-07-13T10:10:38", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Climbs 5.1% as Shares Approach Resistance at $1.08 - Max Pain Level", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPdmo4OFlrR2xiLWNTLVlZSUUtZ2hEQ19zeWgtMUd3dnEwTVR2ZFJfQlhNTzlBTUxmOFJ3MXd2Z3BtSTlTZDlJLWxQcjB6SDBYZXoyN2JvUUl0OUhNSzVBTmdpMko4cFNFMXVEbTA1QkE3N3JzanhHUm9Rby1aMGJ6b1J4YmxRZjNDRnA3cnN6U2NKSlVTSVlWNUtZWWxjS1hVWFd2WlI5YV9kT2l1cDNIX2c2WUZZUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T18:46:27+00:00", "published_display": "12 Jul 2026 18:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxNSTFCMlJGcEpUcEdfSWNlSHZIVjM5X1lKLXFtM1VreHktdko2cEZDcV9ramhXa0ZsYnRpUVdXQkp3S3F4dk9adERIcno5eWtkZ3RuUVZaZzVtSTdmTzdpNjhjUFE4ckI2Zm5UVDhnLU84ckFRTkVnTW40UEFUZVZfczMxUmltZE1xdjk4Y3dDeEd2RTNmaEhoMDhNSlhLTy1tMXJ4UXFWQjUtc1VacGdJM2twU2pnMFVWVm5MVHdZd0NnTFJ2T2s5cTZlOFhhWndMa05qcmRLQkdVZ3Fmd1loS0NxUkctMkF1ekI5Y1BrTVRManVKbnVWSkNfWXJKc3JSbWdQdDhZVC14Q3BmSncza1BOWkdldVptUkhoelE5Zkw1TUp4dkxuY2xR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T16:15:00+00:00", "published_display": "10 Jul 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Stock Forecast & Analyst Ratings", "summary": "This article provides a stock forecast and analyst ratings for CytoMed Therapeutics (GDTC). It includes key metrics such as the stock price, market cap, 52-week range, volume, and average volume. The article also touches upon the company's financial performance, analyst price tar", "url": "https://www.moomoo.com/stock/GDTC-US/forecast?chain_id=Name1K9-3FXPhg.1l0a440&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A59,%22f%22%3A%22www.moomoo.com%2Foptions%2FCOHR260501C330000-US%22%7D", "source_name": "Moomoo", "published_at": "2026-07-10T16:41:18", "published_display": "10 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of CytoMed Therapeutics Limited \u2013 NASDAQ:GDTC", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOM3dOWXJwWjF3QkIwdFBYaGhHQWxhNk9UT1R2OS0wZjY2QzlJVUlHMEJvVm1FeUF0QjVaQUh6MDlya2FUVXVUZFNxejNpQUszTmRJTV8waFlfNzBRMTJnUDNfYW5FSjVfd0dyQS1iVktFdEJVMmwxeVhHcDl5UDFBOFhDY0lpWkJzc3VTbWI1S2JLWlFYTEhyZDV0ekl1c19FVkl0UkN3c2ZaNC1MZFE?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T04:10:56+00:00", "published_display": "10 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (NASDAQ: GDTC) \u2013 A Rising Star in Singapore\u2019s Cancer Biotechnology Sector", "summary": "CytoMed Therapeutics Ltd (NASDAQ: GDTC), a clinical-stage biotech company, is making strides in developing affordable cancer therapies using patented allogeneic Gamma Delta T Cells. The company is currently conducting clinical trials in Singapore and plans to expand to Malaysia, ", "url": "https://www.financialcontent.com/article/getnews-2026-7-9-cytomed-therapeutics-ltd-nasdaq-gdtc-a-rising-star-in-singapores-cancer-biotechnology-sector", "source_name": "FinancialContent", "published_at": "2026-07-09T18:39:57", "published_display": "09 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC - CytoMed Therapeutics Ltd Options", "summary": "This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its last close price, market capitalization, income, sales, key financial ratios, and stock performance metrics. It lists various operational and financial indicators, such as ROA, R", "url": "https://finviz.com/stock?t=GDTC&p=d&b=2&ty=oc", "source_name": "Finviz", "published_at": "2026-07-06T16:09:27", "published_display": "06 Jul 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC - CytoMed Therapeutics Ltd Volatility & Greeks", "summary": "This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's volatility and various financial ratios, offering a snapsho", "url": "https://finviz.com/stock?t=GDTC&b=2&p=d&r=m1&ty=ocv&e=2026-03-02", "source_name": "Finviz", "published_at": "2026-07-03T18:40:32", "published_display": "03 Jul 2026 18:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank", "summary": "CytoMed Therapeutics chairman, Choo Chee Kong, is increasing his personal stake in the company by acquiring up to 200,000 shares and also invested S$300,000 in CytoMed\u2019s subsidiary, LongevityBank Pte Ltd, through his wholly owned EP Capital Inc. This investment will double EP Cap", "url": "https://www.theglobeandmail.com/investing/markets/stocks/GDTC-Q/pressreleases/2631074/cytomed-chairman-boosts-personal-stake-and-funds-rd-expansion-at-longevitybank/", "source_name": "The Globe and Mail", "published_at": "2026-06-27T16:09:27", "published_display": "27 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Limited Actuals & Estimates (NASDAQ:GDTC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOaW5keFV3amwtM01uQ0JXNF85NHlDb0NFM3VmdDVqS3dKUVRjNFB2YjNjS3VvV3lHWHZ1VUkwWGRHSVFpVVZiTmh2VnUxSzRhMy1iNlhhSkFuU2pYbmRwMFJFcFBCOUFDdXdFYWNtLWVMMUtRNnc0OE9uQ3JxbDlkWVZtQ1dJUQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T05:09:55+00:00", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K CytoMed Therapeutics Ltd For: 23 June", "summary": "This article announces the filing of Form 6K by CytoMed Therapeutics Ltd for June 23. It includes disclaimers about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate and that investors should be f", "url": "https://m.uk.investing.com/news/stock-market-news/form-6k-cytomed-therapeutics-ltd-for-23-june-93CH-4740808?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-23T22:10:44", "published_display": "23 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com", "summary": "This article provides details of a Form 6K filing by CytoMed Therapeutics Ltd for June 23. The content is brief, primarily serving as a notification of the filing, and includes general financial market data such as indices, commodities, bonds, and shares, which are not directly r", "url": "https://ng.investing.com/news/stock-market-news/form-6k-cytomed-therapeutics-ltd-for-23-june-93CH-2570533", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T17:24:00", "published_display": "23 Jun 2026 17:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D", "summary": "CytoMed Therapeutics' Chairman and Director, Choo Chee Kong, plans to acquire up to 200,000 company shares through private cash transactions, demonstrating increased personal exposure to the stock. Separately, his entity, EP Capital Inc., invested S$300,000 (approximately US$250,", "url": "https://www.stocktitan.net/sec-filings/GDTC/6-k-cyto-med-therapeutics-ltd-current-report-foreign-issuer-1ca287e3e827.html", "source_name": "Stock Titan", "published_at": "2026-06-23T16:10:16", "published_display": "23 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Holds Flat at $1.09 as Trading Range Narrows - Synthetic Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNM2NaQ3Ixb2N5ZUJIN2trSDg4ZGQxNEFDb0lrR1RWN2RzV3FZbnpSUXROd1R6LXU2aGxlOVBNcG9KVkNpcndMcnlBcFlEblZPcU1UNU9oYjF3SW1PY0RodU85QUdua2ppMHlTZ2RGZWQ0UnhsckNNQWJOdEFSbzN1QVZtV0tEQmZ3N0txbzI3UU5PbmhMOGRzcS1QVTlrZEVrYnZqQVFRdDlCdVZiLURwV0Vn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), focusing on support, resistance, indicators, and moving averages. It synthesizes various technical indicators like MACD, RSI, and MA to offer a comprehensive outlook. The analysis indicates a \"Sell\" si", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T08:11:11", "published_display": "18 Jun 2026 08:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides an analysis of CytoMed Therapeutics Ltd (GDTC) valuation metrics, specifically Price-to-Earnings (P/E), Price-to-Book (P/B), and Fair Value. It explicitly states that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. The p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:39:48", "published_display": "18 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for CytoMed Therapeutics Ltd (GDTC), focusing on future EPS and revenue growth estimates. It notes that relevant data has not yet been disclosed by the company, thus no forecast figures are available. However, analysts forecast a price t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:08:47", "published_display": "18 Jun 2026 06:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Institutional Confidence", "summary": "This article provides details on the institutional confidence in CytoMed Therapeutics Ltd (GDTC), including its stock performance, market capitalization, and key institutional shareholders. It lists several institutional investors and individual shareholders, along with their sha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:08:47", "published_display": "18 Jun 2026 06:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for CytoMed Therapeutics Ltd (GDTC), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Sharpe Ratio, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T03:40:21", "published_display": "18 Jun 2026 03:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of CytoMed Therapeutics Ltd's (GDTC) shareholder structure, detailing major shareholders and institutional holdings. It lists the proportion held by key entities like Glorious Finance Limited and mDR Limited, alongside a breakdown by shareholder ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:32", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for CytoMed Therapeutics Ltd (GDTC), focusing on its business segments, regional revenue, and profit contribution. It states that relevant data for these categories have not yet been disclosed by the company. The page also includes current", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:32", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market", "summary": "CytoMed Therapeutics director and ten percent owner Choo Chee Kong purchased 112,000 Ordinary Shares in an open-market transaction at $1.1498 per share, totaling $128,778. Following this acquisition, Choo Chee Kong directly owns 430,324 Ordinary Shares. The filing indicates a pos", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-4-cyto-med-therapeutics-ltd-insider-trading-activity-3910678c3d24.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:40:18", "published_display": "15 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: Director at $GDTC Buys 112,000 Shares | GDTC Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPeVpXWDBDb3hBaHdUbl85dnFSaHZPNnFqazh5NmN0TjgxRVg2a2lEcW51MlV6cDYxMndpTkFjYlJtb0tXZFV6dnA5cGNFR19za2FEcFA2amVrSkJIQ1ByMHAwWGZiU0tfZmVRLUZoUnU4eGVOYXB0b2diajRLbVpfSmVRMFpHLUdoRVE2cElKWERVVWpSX2ozZHZB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Purchase: Director at $GDTC Buys 112,000 Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxObUxZQmY0Rk5WUlNldURwTnlJakJwcWtRTEJkc0VjWXdBMGIwTUVQUmRHZjR0MTAyZmVVdXZaZHNUUTBnTnZSTDhLV1F1YWJ2OC1Eb29RRG9zeE5PRlFmWkt2TnY1Q0NHVVBIc0Zpb0JrcUI5VzlSZXhBVGFITzQxVkRPVU9JLTYwckJpeGNZSllDd3p1OXdnWEJ3?oc=5", "source_name": "Moomoo", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (Nasdaq:GDTC) - Stock Analysis", "summary": "This article provides a stock analysis of CytoMed Therapeutics (Nasdaq:GDTC), highlighting its status as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies. It details the company's financial performance, including declining earnings and an undervalu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gdtc/cytomed-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-05T02:09:12", "published_display": "05 Jun 2026 02:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals", "summary": "CytoMed Therapeutics (NASDAQ: GDTC) shareholders approved all ten proposals at its Annual General Meeting (AGM) held on May 22, 2026, in Singapore. These approvals included adopting financial statements, re-electing directors Dr. Yew Chak Hua and Dr. Toh Keng Kiat, waiving the Si", "url": "https://www.stocktitan.net/sec-filings/GDTC/6-k-cyto-med-therapeutics-ltd-current-report-foreign-issuer-56e566ca6d2b.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:40:30", "published_display": "03 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into Focus - Volume Dry Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNYnRHUTMxaGpYM1FfeGtlOG1TM0szWlFxUEk0LU1ZNDRlWTZzYkJHLXJlUm1PWnlJcGF2MGx0MTF1bkFKMVBYVGU3MHFkbUsxR3hPd01WSlBNc1BTenQ0S0RkbHBYVnAzRlA0MHJxc215eXd5NEF1SEZBSE5mcUw5c3poRnBZTjFJbTIyMTRTamYxUkcya3J3ME9Dc1lHckRYYkhwSFMtZ0JBM3AyMUMtVFpBMVUxWHJC?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC - CytoMed Therapeutics Ltd Stock Price and Quote", "summary": "This article provides a detailed stock price and quote for CytoMed Therapeutics Ltd (GDTC), including its last closing price, financial metrics, and recent news. It highlights various financial data points like market cap, income, sales, and insider ownership, alongside a chronol", "url": "https://finviz.com/stock?t=GDTC", "source_name": "Finviz", "published_at": "2026-06-01T00:14:03", "published_display": "01 Jun 2026 00:14", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares", "summary": "CytoMed Therapeutics director Toh Keng Kiat has reported an initial beneficial ownership of 4,000 Ordinary Shares in the company. This disclosure is a routine Form 3 filing with the SEC and signifies an existing holding rather than a new transaction. The shares are directly owned", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-2a9b9fb9de28.html", "source_name": "Stock Titan", "published_at": "2026-05-26T12:40:22", "published_display": "26 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Ltd - A Rising Star in Singapore's Cancer Biotechnology Sector", "summary": "CytoMed Therapeutics Ltd, a clinical-stage biotech company based in Singapore, is making significant strides in developing affordable cancer therapies using allogeneic Gamma Delta T Cells. Through strategic acquisitions and a focus on global expansion, particularly in China and I", "url": "https://www.openpr.com/news/4521685/cytomed-therapeutics-ltd-a-rising-star-in-singapore-s-cancer", "source_name": "openPR.com", "published_at": "2026-05-21T10:40:13", "published_display": "21 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Limited is accelerating its international expansion", "summary": "CytoMed Therapeutics Limited is expanding its international presence, starting with a name change for its subsidiary to CytoMed International Pte. Ltd. The company aims to explore global opportunities, particularly in Asia and China, through potential joint ventures and medical t", "url": "https://www.openpr.com/news/4516247/cytomed-therapeutics-limited-is-accelerating-its", "source_name": "openPR.com", "published_at": "2026-05-18T05:39:09", "published_display": "18 May 2026 05:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 3] CytoMed Therapeutics Ltd Initial Statement of Beneficial Ownership", "summary": "CytoMed Therapeutics Ltd's Chief Corporate Officer, Tan Yoong Ying, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 25,781 Ordinary Shares with no par value. This SEC filing indicates his existing stake without any recent purchase or ", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-547b5d7a2b42.html", "source_name": "Stock Titan", "published_at": "2026-05-15T22:09:18", "published_display": "15 May 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director Choo Chee Kong details direct and indirect share ownership", "summary": "CytoMed Therapeutics director Choo Chee Kong filed an initial Form 3 detailing his beneficial ownership in the company. The filing reports direct ownership of 318,324 Ordinary Shares and indirect ownership through Glorious Finance Limited (2,075,310 shares) and EP Capital Inc. (1", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-afcc166940b2.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:10:35", "published_display": "15 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) CFO reports holding 25,781 ordinary shares", "summary": "CytoMed Therapeutics' CFO, Yvonne Goh, has filed an initial insider ownership report (Form 3) showing she directly holds 25,781 Ordinary Shares in the company. This filing simply reports her existing stake and does not indicate any recent purchases, sales, or option exercises. Th", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-74ea2aa207c6.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:10:35", "published_display": "15 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (NASDAQ: GDTC) director reports 2,469 ordinary shares on Form 3", "summary": "CytoMed Therapeutics director Yew Chak Hua has reported an initial ownership of 2,469 ordinary shares on Form 3, establishing his status as a director with a direct stake. This filing indicates current holdings upon becoming a director and does not reflect any recent buying or se", "url": "https://www.stocktitan.net/sec-filings/GDTC/form-3-cyto-med-therapeutics-ltd-initial-statement-of-beneficial-owne-2287f13bdf01.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:10:34", "published_display": "15 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] CytoMed Therapeutics Ltd SEC Filing", "summary": "This article reports on a Form 144 SEC filing by CytoMed Therapeutics Ltd (GDTC). The filing indicates a proposed sale of 117,337 ordinary shares with an aggregate market value of $98,093.73, acquired on April 22, 2021, via a share subscription from the issuer. The sale is schedu", "url": "https://www.stocktitan.net/sec-filings/GDTC/144-cyto-med-therapeutics-ltd-sec-filing-704d6fc27a25.html", "source_name": "Stock Titan", "published_at": "2026-05-13T14:39:01", "published_display": "13 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "The page displays real-time and delayed quotes for CytoMed Therapeutics Ltd (GDTC) on Nasdaq, showing a current price of 0.809 USD with a 3.72% increase. It presents an overview of the company, financial data, and discussion sections, along with a market cap and P/E TTM informati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gdtc/comments", "source_name": "TradingKey", "published_at": "2026-05-11T19:40:32", "published_display": "11 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics Strengthens Future with Advanced Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxOeE1RMy1ya3k5WFNwX05WcjB6NXhsbnpucmhhc21vRWIwTC14d2VRcDV5WVNlNFV2ckRmZHZ3aWxjc2xCWkZ2Y21rblg2NEJkeEdEX1B2WWZPOVJLUFNLNGVrZ0drNl9qUUFvVFoyUkVodXBXdUEybUoxMDFHenBzVk82TmpqYVZ6dER5RQ?oc=5", "source_name": "timothysykes.com", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxOEp3YktYbS1xUlBQVUNTQWwya2FqcHNEOXBqVTRWSjBQT3Y5NmdvbVFMVjVyNWdGNm8ybkNXb1RFamRFb1hFZTlLdXZIQVMyOC1j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:24:35+00:00", "published_display": "25 Apr 2025 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GDTC Stock Price and Chart \u2014 NASDAQ:GDTC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9iSmFjbDI4VjQzaVc5UTBpS3JoZUQzUlQ4OHRvemZaNXBGQ3cxdVZmd1JaeW1FRzZ6c1VoZC10eUtvRGZxR01zMmtad19WMDhQNHc5aGtDLWl6QzdS?oc=5", "source_name": "TradingView", "published_at": "2024-01-23T08:00:00+00:00", "published_display": "23 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Better Therapeutics (BTTX) Stock Up 39% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxPbDhRalpFYmJqdzFxRVktanhUVHEzbFVLMEFvTXVmbHdlY0h3OWs2cXRRVEx4MkhCY2NpZkVkbmgyRlhYS1BCTFhGR2M5eWQ0NHRsS0hISWxGNGpTRnpMMjR1bHVtSUliZVJBc1dveWJvQVBHLU56bkxRRk9jWkE5a3B6WWF6UnBXREZ6ZQ?oc=5", "source_name": "InvestorPlace", "published_at": "2023-07-11T07:00:00+00:00", "published_display": "11 Jul 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CytoMed Therapeutics (GDTC) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9CNjZVTVVtR0JLQW9pcGdmYjdYNWhXT1JvWlRnOG9sMkRRcEZhSm11TXFkTWVlTHV0eTB6MVF6NENFQUFrc1FVLWhRT0c0UQ?oc=5", "source_name": "Stock Titan", "published_at": "2023-04-14T00:23:14+00:00", "published_display": "14 Apr 2023 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 50, "sentiment_summary": {"positive": 8, "negative": 5, "neutral": 37, "score": 52, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 1.03, "latest_week": "2026-07-10", "one_week_move": 5.6, "four_week_move": -9.6, "twelve_week_move": 2.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.599772, "market_dynamics_buy_signal": false, "relative_strength": -40.42578, "fair_value_gap": -54.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.6163, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.6% over one week, -9.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "TradingKey", "count": 8}, {"label": "Market source", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "dars.gov.et", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "openPR.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 11}, {"label": "Deals and strategy", "count": 6}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.6% over one week, -9.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)"}], "updated_at": "2026-07-16T06:03:44.080334+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}